ES2922978T3 - Derivados de pirrolidina - Google Patents

Derivados de pirrolidina Download PDF

Info

Publication number
ES2922978T3
ES2922978T3 ES16858971T ES16858971T ES2922978T3 ES 2922978 T3 ES2922978 T3 ES 2922978T3 ES 16858971 T ES16858971 T ES 16858971T ES 16858971 T ES16858971 T ES 16858971T ES 2922978 T3 ES2922978 T3 ES 2922978T3
Authority
ES
Spain
Prior art keywords
aryl
alkyl
azabicyclo
ylethynyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16858971T
Other languages
English (en)
Spanish (es)
Inventor
Li Chen
Yuejiao Duan
Jin She
Chengde Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hua Medicine Shanghai Ltd
Original Assignee
Hua Medicine Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hua Medicine Shanghai Ltd filed Critical Hua Medicine Shanghai Ltd
Application granted granted Critical
Publication of ES2922978T3 publication Critical patent/ES2922978T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES16858971T 2015-10-28 2016-10-21 Derivados de pirrolidina Active ES2922978T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510713865.7A CN106632243B (zh) 2015-10-28 2015-10-28 吡咯烷衍生物
PCT/CN2016/102946 WO2017071536A1 (en) 2015-10-28 2016-10-21 Pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
ES2922978T3 true ES2922978T3 (es) 2022-09-22

Family

ID=58629839

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16858971T Active ES2922978T3 (es) 2015-10-28 2016-10-21 Derivados de pirrolidina

Country Status (17)

Country Link
US (1) US10328054B2 (enExample)
EP (1) EP3371163B1 (enExample)
JP (1) JP6877771B2 (enExample)
KR (1) KR102815874B1 (enExample)
CN (2) CN106632243B (enExample)
AU (1) AU2016345244B2 (enExample)
BR (1) BR112018008204B1 (enExample)
CA (1) CA3000794C (enExample)
DK (1) DK3371163T3 (enExample)
ES (1) ES2922978T3 (enExample)
HU (1) HUE058899T2 (enExample)
IL (1) IL258517B (enExample)
MX (1) MX385587B (enExample)
RU (1) RU2740019C1 (enExample)
TW (1) TWI725998B (enExample)
WO (1) WO2017071536A1 (enExample)
ZA (1) ZA201802235B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
CN106632243B (zh) * 2015-10-28 2019-03-15 华领医药技术（上海）有限公司 吡咯烷衍生物
KR102740618B1 (ko) * 2021-11-17 2024-12-10 유노비아 주식회사 아이속사졸 유도체의 제조 방법 및 그의 중간체
CN119569744B (zh) * 2024-11-19 2026-01-02 武汉大学人民医院（湖北省人民医院） 吡喃吡啶酮生物碱类化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503646D0 (en) 2005-02-22 2005-03-30 Novartis Ag Organic compounds
CN101990536B (zh) * 2008-01-18 2014-09-03 上海靶点药物有限公司 基于吡咯烷的化合物
TW201116532A (en) * 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2012152854A1 (en) * 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
WO2014124560A1 (en) * 2013-02-18 2014-08-21 Hua Medicine (Shanghai) Ltd. Mglur regulators
CN106632243B (zh) * 2015-10-28 2019-03-15 华领医药技术（上海）有限公司 吡咯烷衍生物

Also Published As

Publication number Publication date
WO2017071536A1 (en) 2017-05-04
JP2018532778A (ja) 2018-11-08
KR102815874B1 (ko) 2025-06-02
CN108349935B (zh) 2021-02-05
CN106632243B (zh) 2019-03-15
MX385587B (es) 2025-03-18
EP3371163A4 (en) 2019-05-01
KR20180070693A (ko) 2018-06-26
DK3371163T3 (da) 2022-07-04
US20180318254A1 (en) 2018-11-08
BR112018008204B1 (pt) 2023-12-26
EP3371163A1 (en) 2018-09-12
EP3371163B1 (en) 2022-03-30
MX2018004868A (es) 2018-11-09
CN108349935A (zh) 2018-07-31
RU2740019C1 (ru) 2020-12-30
IL258517A (en) 2018-05-31
JP6877771B2 (ja) 2021-05-26
HUE058899T2 (hu) 2022-09-28
AU2016345244B2 (en) 2020-07-09
CN106632243A (zh) 2017-05-10
TW201718542A (zh) 2017-06-01
BR112018008204A2 (pt) 2018-12-18
HK1254456A1 (en) 2019-07-19
CA3000794C (en) 2024-01-16
CA3000794A1 (en) 2017-05-04
IL258517B (en) 2020-05-31
TWI725998B (zh) 2021-05-01
ZA201802235B (en) 2019-07-31
AU2016345244A1 (en) 2018-04-26
US10328054B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
CN109153643B (zh) 取代的吲哚mcl-1抑制剂
CN107108581B (zh) 作为强效rock抑制剂的回接苯甲酰胺衍生物
JP7130873B2 (ja) バニン阻害剤としてのヘテロ芳香族化合物
KR20190091537A (ko) C-kit 억제제로서의 아미노티아졸 화합물
KR20180041112A (ko) Cdk 억제제로서의 치환된 헤테로사이클릴 유도체
JP2021505684A (ja) ヒストンデアセチラーゼ６阻害剤としての１，２，４−オキサジアゾール誘導体
JP6877771B2 (ja) ピロリジン誘導体
CA2994917A1 (en) 3-indol substituted derivatives, pharmaceutical compositions and methods for use
WO2012138648A1 (en) Compositions and methods for modulating lpa receptors
JPWO2004069824A1 (ja) ピラゾール誘導体
AU2014234909A1 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
TWI434840B (zh) 吡唑啶－３－酮衍生物
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
CN112930346A (zh) 作为nadph氧化酶抑制剂的新型化合物
JP2016535097A (ja) ４−（インドール−３−イル）−ピラゾール誘導体、医薬組成物および使用のための方法
KR20210018900A (ko) Lpa1 수용체 안타고니스트로서의 알콕시-치환된 피리디닐 유도체 및 섬유증의 치료에서의 이의 용도
WO2014124560A1 (en) Mglur regulators
JP7235859B2 (ja) 新規なチアゾール誘導体及びその薬学的に許容される塩
WO2017018475A1 (ja) 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
HK40065957A (en) Substituted heterocyclyl derivatives as cdk inhibitors
HK1254456B (en) Pyrrolidine derivatives
KR20210108684A (ko) 신규한 Pim 키나아제 억제제 및 이의 용도
BR122023020299A2 (pt) Composto, uso de um composto, composição farmacêutica e processo para preparação de um composto
BR112017026088B1 (pt) Composto, uso de um composto e composição farmacêutica